Skip to main content

Recurrent/Refractory CNS clinical trials at UCSF
1 in progress, 1 open to new patients

  • Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

    open to eligible people ages 18 years and up

    This is a Phase I study, which means that the goal is to see if the study treatment is safe. The purpose of this study is to test the safety of Lenalidomide at different dose levels, and to test the safety of Lenalidomide alone or in combination with Rituximab (also known as Rituxan®).

    San Francisco, California